COVID-19에 대한 청폐배독탕의 연구 동향 분석

키워드

참고문헌 (54)

1. 장인수, "코로나바이러스감염증-19한의진료 권고안", pp.1~52 (2020), 사단법인대한한의사협회
2. Lau JT, "The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life:a prospective cohort study", Journal of Alternative & Complementary Medicine, 11(1), pp.49~55 (2005)
3. Yang ZF, "Developing influenza treatments using traditional Chinese medicine", Science, 347(6219), pp.S35~ (2015)
4. Jiang L, "Chinese medicinal herbs for influenza", Cochrane Database of Systematic Reviews, (3) (2013)
5. Jiang YJ, "Study on Pneumonia Prescription of Traditional Chinese Medicine to Prevent Novel Coronavirus Infection in Different Regions Based on Data Mining", World Chinese Medicine, 15(3), pp.325~331 (2020)
6. Wang X, "Prevention and treatment of viral respiratory infections by traditional Chinese herbs", Chinese medical journal, 127(7), pp.1344~1350 (2014)
7. Shen AM, "TCM Theory analysis of Qing-Fei-Pai-Du-Tang in treating COVID-19", Liaoning Journal of Traditional Chinese Medicine, (3), pp.106~108 (2020)
8. 恵子小, "COVID-19感染症に対する漢方治療の 考え方", 日本の感染学会, 3, pp.1~5 (2020)
9. Yang Y, "Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2):a review and perspective", International journal of biological sciences, 16(10), pp.1708~1717 (2020)
10. 이범준, "코로나바이러 스감염증-19한의지료 지침 2", pp.1~13 (2020), 전국한의과대학폐계내과협의회
11. 고흥, "코로나바이러스감염증-19한의전화진료 가이드", pp.1~45 (2020), 사단법인대한한의사협회
12. 薛伯寿, "“清肺排毒汤”快速有效 治疗新型冠状病毒肺炎的中医理论分析", 中医杂志, 61(6), pp.461~462 (2020)
13. Wang RQ, "Clinical Observation of Qingfeipaidu Decoction in the Treatment of COVID-19", Pharmacology and Clinics of Chinese Materia Medica, 36(1), pp.13~18 (2020)
14. 路志正路, "“清肺排毒汤”彰显中医药抗疫疗效 与自信", 中医杂志, 10, pp.833~834 (2020)
15. Wu H, "Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology", Acta Pharmaceutica Sinica, 55(3), pp.374~383 (2020)
16. Zhao J, "Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network pharmacology", Chin Trad Herbal Drugs, 51(4), pp.829~835 (2020)
17. 진조조, "중의치법과 방제", pp.306~527 (2009), 정담
18. Zhang HL, "Study on the Mechanism of Maxing Shigan Decoction in the Treatment of the Severe Novel Coronavirus Pneumonia Based on Network Pharmacology", Journal of Chinese Medicinal Materials, (03), pp.1~8 (2000)
19. Hsieh CF, "Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus", Journal of ethnopharmacology, 143(1), pp.57~67 (2012)
20. Zhong Y, "Effect of Maxing Shigan Tang on H1N1 influenza A virus-associated acute lung injury in mice", Intervirology, 59(5-6), pp.267~274 (2016)
21. Kao ST, "The effects of Ma-Xing-Gan-Shi-Tang on respiratory resistance and airway leukocyte infiltration in asthmatic guinea pigs", Immunopharmacology and immunotoxicology, 23(3), pp.445~458 (2001)
22. 吉益東洞, "약징", pp.95~100 (2010), 청홍
23. 한방약리학교재편찬위원회, "한방약리학", pp.119~130 (2015), 신일북스
24. 한의과대학방제학교실, "방제학", pp.504~505 (2009), 영림사
25. Matsukawa T, "Angiotensin II-stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans", American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 300(3), pp.R624~R629 (2011)
26. Boldt J, "Physiology and pathophysiology of the natriuretic peptide system. Yearbook of Intensive Care and Emergency Medicine", pp.101~109 (2006), Springer
27. Task Force for Clinical Practice Guidelines (CPG-TF) Committee for EBM, "Clinical Practice Guidelines Containing kampo Products in Japan(KCPG) Appendix 2018", The Japan Society for Oriental Medicine (JSOM), 1~8 (2019)
28. 中国中西医结合杂志, "新型冠状病毒肺炎诊疗方 案(试行第五版修正版)", 中国中西医结合杂志, 40(2), pp.136~138 (2020)
29. Furukawa M, "Inhibitory effects of kampo medicine on Epstein-Barr virus antigen induction by tumor promoter", Auris Nasus Larynx, 17(1), pp.49~54 (1990)
30. Yamashiki M, "Effects of the Japanese herbal medicine"Sho-saiko-to"(TJ-9)on interleukin-12 production in patients with HCV-positive liver cirrhosis", Clinical and Developmental Immunology, 7(1), pp.17~22 (1999)
31. Yamashiki M, "Effects of the Japanese herbal medicine"Sho-Saiko-To"(TJ-9)on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C", Hepatology, 25(6), pp.1390~1397 (1997)
32. Yamashiki M, "In vitro effects of Sho-saiko-to on production of granulocyte colony-stimulating factor by mononuclear cells from patients with chronic hepatitis C", International journal of immunopharmacology, 19(7), pp.381~385 (1997)
33. Kubo T, "Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children", Phytomedicine, 14(2-3), pp.96~101 (2007)
34. 川村研一, "インフルエンザ患者に対する麻黄湯の 有効性の検討", 日本臨床内科医会会誌, 22(4), pp.435~438 (2007)
35. 芦原貴司, "ザナミビルに麻黄湯を併用し緩徐な 解熱が得られた小児インフルエンザの1症例", 漢方医学, 34(2), pp.201~203 (2010)
36. 陈豪, "射干麻黄汤对哮 喘性肺炎大鼠肺部炎症反应及免疫反应的影响", 广州中医药大学学报, 37(2), pp.317~323 (2020)
37. Shijie Z, "Mao-to prolongs the survival of and reduces TNF-αexpression in mice with viral myocarditis", Evidence-Based Complementary and Alternative Medicine, 7(3), pp.341~349 (2010)
38. Orihara Y, "A silkworm- baculovirus model for assessing the therapeutic effects of antiviral compounds:characterization and application to the isolation of antivirals from traditional medicines", Journal of general virology, 89(1), pp.188~194 (2008)
39. Murakami T, "Ephedrae herba, a component of Japanese herbal medicine Mao-to, efficiently activates the replication of latent human immunodeficiency virus type 1 (HIV-1) in a monocytic cell line", Biological and Pharmaceutical Bulletin, 31(12), pp.2334~2337 (2008)
40. Park JS, "Anti-inflammatory mechanisms of isoflavone metabolites in lipopolysaccharide- stimulated microglial cells", Journal of Pharmacology and Experimental Therapeutics, 320(3), pp.1237~1245 (2007)
41. Kang KA, "Protective effect of irisolidone, a metabolite of kakkalide, against hydrogen peroxide induced cell damage via antioxidant effect", Bioorganic & medicinal chemistry, 16(3), pp.1133~1141 (2008)
42. Zhao M, "Systems pharmacology dissection of multi-scale mechanisms of action of Huo- Xiang-Zheng-Qi formula for the treatment of gastrointestinal diseases", Frontiers in Pharmacology, 9, pp.1448~ (2019)
43. Li X, "Tangeretin inhibits oxidative stress and inflammation via upregulating Nrf-2 signaling pathway in collagen-induced arthritic rats", Pharmacology, 104(3-4), pp.187~195 (2019)
44. Zhao S, "Anti-inflammatory effects of Zhishi and Zhiqiao revealed by network pharmacology integrated with molecular mechanism and metabolomics studies", Phytomedicine, 50, pp.61~72 (2018)
45. 김성진, "지각 약침액의 항산화 및 항염증 효과에 관한 연구", Korean Journal of Acupuncture, 27(2), pp.13~24 (2010), 경락경혈학회
46. 최가영, "산약 추출물의 항산화 및 항염증에 관한 실험적 연구", 대한한방내과학회지, 31(2), pp.290~297 (2010), 대한한방내과학회
47. Kim MJ, "Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis", International immunopharmacology, 4(12), pp.1489~1497 (2004)
48. 양정민, "山藥의 항산화 작용에 대한 단백질체 분석 연구", 대한한방부인과학회지, 21(2), pp.108~124 (2008), 대한한방부인과학회
49. 전영준, "산약의 HeLa cell 분화에 미치는 영향과 항산화효과에 대한연구", 대한한방부인과학회지, 20(2), pp.139~154 (2007), 대한한방부인과학회
50. 신상우, "대표적 보기약인 인삼, 당삼, 황기, 백출, 산약 물추출액의 면역조절효과 비교", 동의생리병리학회지, 18(4), pp.1140~1146 (2004), 한의병리학회
51. Ryu HC, "A study on proper dosage of Ma-huang(麻黃)", The Journal of Korean Medical Association of Clinical Sanghan-Geumgwe, 5(1), pp.101~111 (2013)
52. Kim HS, "A Study for Safe Dose and Clinical Use of Glycyrrhizae Radix in Shanghanlun", The Journal of Korean Medical Association of Clinical Sanghan-Geumgwe, 8(1), pp.1~23 (2016)
53. 이인, "와파린과 상호작용하는 한약재에 대한 고찰", 대한한방내과학회지, 33(2), pp.160~171 (2012), 대한한방내과학회
54. Ishizaki T, "Pneumonitis during interferon and", or herbal drug therapy in patients with chronic active hepatitis, 1996, pp.9(12), 2691~2696

관련 논문AI추천